Utilization of immunotherapy in patients with cancer treated in routine care settings: a population-based study using health administrative data
J Raphael, L Richard, M Lam, PS Blanchette… - The …, 2022 - academic.oup.com
Introduction The introduction of immunotherapy (IO) in the treatment of patients with cancer
has significantly improved clinical outcomes. Population level information on actual IO …
has significantly improved clinical outcomes. Population level information on actual IO …
Does it fit in your pocket? economic burden of PD-1 inhibitors' toxicity in the supplementary health system: evidence from Brazil
HS Duarte, CRP da Veiga, CP da Veiga… - BMC Health Services …, 2023 - Springer
Background A full understanding of the economic burden associated with treatment-related
adverse events (AEs) can aid estimates of the incremental costs associated with …
adverse events (AEs) can aid estimates of the incremental costs associated with …
Real-world incidence of severe myelosuppression among chronic myeloid leukemia patients treated with imatinib in Ontario
N McKenzie - 2024 - dalspace.library.dal.ca
Imatinib, approved in 2001 for the treatment of chronic myeloid leukemia (CML) based on its
remarkable efficacy, was associated with severe hematologic adverse events in clinical …
remarkable efficacy, was associated with severe hematologic adverse events in clinical …
